Trastuzumab: Anti-HER2 antibody for treatment of metastatic breast cancer

Cancer Practice

Volumn 7, Issue 1, 1999, Pages 48-50

  Wong, Wendy M ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AUTOANTIBODY; TRASTUZUMAB; UNCLASSIFIED DRUG; ANTINEOPLASTIC AGENT; EPIDERMAL GROWTH FACTOR RECEPTOR 2; MONOCLONAL ANTIBODY;

BREAST CANCER; CANCER CHEMOTHERAPY; CANCER PATIENT; CARDIOTOXICITY; CHILL; DIARRHEA; DOSE RESPONSE; DRUG APPROVAL; FEVER; GENE EXPRESSION REGULATION; HUMAN; INSOMNIA; NAUSEA; ONCOGENE NEU; PROTO ONCOGENE; REVIEW; RHINITIS; VOMITING; BREAST TUMOR; FEMALE; IMMUNOLOGY; METASTASIS; PATHOLOGY;

ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; BREAST NEOPLASMS; FEMALE; HUMANS; NEOPLASM METASTASIS; RECEPTOR, ERBB-2;

EID: 0032600294     PISSN: 10654704     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1523-5394.1999.07108.x     Document Type: Review

References (12)

1. McNeil C. Herceptin raises its sights beyond breast cancer. J Natl Cancer Inst. 1998;90:882-883.
2. Dickson RB, Lippman ME. Molecular biology of breast cancer. In: DeVita VT Jr, Hellman S, Rosenberg SA, eds. Cancer: Principles & Practice of Oncology. Philadelphia: Lippincott-Raven Publishers; 1997:1551.
3. Harris J, Morrow M, Norton L. Malignant tumors of the breast. In: DeVita VT Jr, Hellman S, Rosenberg SA, eds. Cancer: Principles & Practice of Oncology. Philadelphia: Lippincott-Raven Publishers; 1997:1557.
4. Tandon AK, Clark GM, Chamness GC, et al. HER2/neu oncogene protein and prognosis in breast cancer. J Clin Oncol. 1989;7:1120-1128.
5. Shepard HM, Lewis GD, Sarup JC, et al. Monoclonal antibody therapy of human cancer: taking the HER2 protooncogene to the clinic. J Clin Immunol. 1991;11:117-127.
6. Drebin JA, Link VC, Greene MI. Monoclonal antibodies reactive with distinct domains of the neu oncogene-encoded p185 molecule exert synergistic anti-tumor effects in vivo. Oncogene. 1988;2:273-277.
7. HER2 monoclonal antibody in patients with HER2/neu-over-expressing metastatic breast cancer. J Clin Oncol. 1996;14: 737-744.
8. HER2 antibody for human cancer therapy. Proc Natl Acad Sci U S A. 1992;89:4285-4289.
9. HER2/neu monoclonal antibody plus cisplatin in patients with HER2/neu-overexpressing metastatic breast cancer refractory to chemotherapy treatment. J Clin Oncol.1998; 16:2659-2671.
10. Cobleigh MA, Vogel CL, Tripathy D, et al. Efficacy and safety of Herceptin (humanized anti-HER2 antibody) as a single agent in 222 women with HER2 overexpression who relapsed following chemotherapy for metastatic breast cancer. Proc Am Soc Clin Oncol. 1998;17:97a.
11. Slamon D, Leyland-Jones B, Shak S, et al. Addition of Herceptin (humanized anti-HER2 antibody) to first line chemotherapy for HER2 overexpressing metastatic breast cancer (HER2+/MBC) markedly increases anticancer activity: a randomized, multinational controlled phase III trial. Proc Am Soc Clin Oncol. 1998; 17:98a.
12. Genentech, Inc. Herceptin® package insert. South San Francisco, Calif: Genentech, Inc.; 1998.